Want to see HOWL full AI Analyst Report?
HOWL Stock Chart & Stats
$0.94
-$0.04(-2.90%)
At close: 4:00 PM EST
$0.94
-$0.04(-2.90%)
Day’s Range― - ―
52-Week Range$0.27 - $2.38
Previous CloseN/A
Volume113.58K
Average Volume (3M)1.22M
Market Cap
$18.39M
Enterprise Value$7.92M
Total Cash (Recent Filing)$46.45M
Total Debt (Recent Filing)$37.65M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding48,596,817
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.48
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.85
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Clinical ReadoutsAnalyst points out that an extended cash runway combined with maturing clinical data from early trials could strengthen the clinical case and reveal pipeline undervaluation, supporting upside potential.
Proprietary Masking TechnologyAnalyst highlights a proprietary masking technology that activates in tumor microenvironments to reduce off-target toxicities and meaningfully improve safety, strengthening the platform's therapeutic appeal.
T‑cell Engager StrategyAnalyst believes the strategic pivot to T cell engagers aligns with strong investor interest and could create nearer-term opportunities by leveraging the masking platform as a differentiator.
Bears Say
Cytokine Tolerability SkepticismAnalyst warns that historical challenges in improving cytokine tolerability have left investors skeptical, characterizing the company as a 'show‑me' story and making fundraising more difficult.
Senior Leadership DeparturesAnalyst points out resignations of the chief financial and medical officers increase uncertainty and could complicate efforts to negotiate a strategic deal or stabilize operations.
Workforce Reductions And Funding RiskAnalyst notes a large workforce reduction intended to preserve cash may indicate difficulties securing external funding or partnerships, increasing execution and financing risk.
Werewolf Therapeutics News
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.27 and its highest was $2.38 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $18.39M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on May 07, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.01.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Overvalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 48,596,817 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went up 9.677%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Technical Analysis
CervoMed
―
NRX Pharmaceuticals
―
Kalaris Therapeutics
―
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
20.31% Insiders
3.24% Mutual Funds
21.79% Other Institutional Investors
52.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---